INS and steatosis: Chronic treatment with a single daily dose of VCE-004.8 for three weeks was sufficient to revert nearly all of these adverse metabolic alterations, since VCE-004.8 treated HFD-animals showed (i) significantly lower BW gain, (ii) reduced fat mass and adiposity –together with increased % lean mass-, (iii) reduced steatosis, (iv) normalized circulating triglycerides and basal glycemia, (v) reduced basal insulinemia, and (vi) significantly improved glucose tolerance and insulin sensitivity.